All In Biotech

Drug Trial Radar · NCT07308782

A Phase Ⅱa Clinical Study of CL-197 Capsules

An Exploratory Pharmacodynamic Clinical Study of CL-197 Capsules in Treatment Naive Patients With Human Immunodeficiency Virus (HIV-1)

Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Nov 29, 2025

Primary completion

Dec 2026

Study completion Mar 2027

Sponsor

Sponsor type
Industry
First posted
Dec 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the antiretroviral activity, safety and pharmacokinetics of single dose of CL-197 capsule in three dose groups administered to antiretroviral treatment-naïve adult participants with human immunodeficiency virus type 1 (HIV-1) infection.

Conditions

  • HIV-1 Infection

Interventions

  • CL-197 capsulesDrug

    Participants will take a single dose of CL-197 capsules at a dose of 10 mg, 30 mg or 60 mg, orally on an empty stomach.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in log10 value of HIV-1 Ribonucleic acid (RNA) on Day 8Time frame: Baseline and Day 8.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Youan Hospital, Capital Medical University

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.